Loading
Overview
RemeGen, based in Yantai and listed in Hong Kong as 9995.HK, developed disitamab vedotin, China's first domestically developed antibody-drug conjugate. Disitamab vedotin, also known as RC48, targets HER2 and is used in gastric and urothelial cancer, and the company's other main product is telitacicept for autoimmune disease. OnCo links it to gastric and HER2-positive breast cancer, to the disitamab vedotin drug record and to Peking University Cancer Hospital. Whether a HER2 ADC with an older payload can find a durable niche as newer HER2 ADCs spread is the open question. Disitamab vedotin has its own page.
Headquarters
Yantai, CN
Scorecard
All companies#138of 1244 companies, score 42
- approved products +6
- phase 3 +3
- phase 1/2 +1
- targets +4
- modalities +4
- regions +1
- 24-month regulatory events +2
- registry trials +21
1 approved, 1 in phase 3, 1 earlier, 2 targets, 113 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2021-08-09 | RemeGen to Pfizer (incl. Seagen) Disitamab vedotin (RC48), HER2 ADC | Licence | $200m | up to $2.4bn | source |
Type
Biotech · 9995.HK
Stage
Public
Website
ApprovedADC
Disitamab vedotin is a Chinese HER2 ADC approved for gastric and bladder cancer, now in global trials with Pfizer.
Phase 2ADC
RC118-ADC is an experimental antibody-drug conjugate from RemeGen in phase 2 trials, aimed at Claudin 18.2.
Phase 3bispecific antibody (PD-1 x VEGF, per the sponsor's pipeline page; form not stated in the registry record)
RC148 is an experimental investigational agent whose form is not stated in the registry from RemeGen in phase 3 trials for non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
Similar pages
- TreatmentToripalimab
Shares A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors, Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer, A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer, A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma.
- TreatmentEpirubicin
Shares Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer, To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer, HER2-positive breast cancer, Gastric & gastro-oesophageal junction cancer.
- CancerHER2-positive gastric cancer
Shares DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy, Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma., Disitamab vedotin, Gastric & gastro-oesophageal junction cancer.
cancers
fronts
drugs
ApprovedADC
Phase 2ADC
Phase 3bispecific antibody (PD-1 x VEGF, per the sponsor's pipeline page; form not stated in the registry record)
institutions
trials
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid TumorsA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally AdvA Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal CancerA Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsA Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsA Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid TumorsA Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsA Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric CancerA Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent oA Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationA Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerEfficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerNeoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast CancerPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without ActRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerTo Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2